抗凝治疗对肝硬化合并门静脉血栓患者的影响:系统评价与Meta分析
该系统评价与Meta分析检索截至2017年2月14日的数据库,纳入8项研究共353例肝硬化合并门静脉血栓患者,比较抗凝治疗(低分子肝素或华法林)与无治疗的效果。抗凝组门静脉血栓再通比例显著高于无抗凝组(71% vs 42%,P<.0001),血栓进展比例显著低于无抗凝组(9% vs 33%,P<.0001),大出血或小出血比例两组无差异(均为11%),抗凝组食管胃静脉曲张破裂出血比例显著低于无抗凝组(P=.04)。
要点
- 抗凝治疗与肝硬化合并门静脉血栓患者再通比例升高相关(71% vs 42%,P<.0001)。
- 抗凝治疗与门静脉血栓进展比例降低相关(9% vs 33%,P<.0001)。
- 抗凝组与无抗凝组大出血或小出血比例无差异(均为11%),抗凝组食管胃静脉曲张破裂出血比例显著更低(P=.04)。
核心结论
- 基于系统评价与Meta分析,肝硬化合并门静脉血栓患者接受抗凝治疗较未接受抗凝治疗再通比例升高、血栓进展比例降低,且大出血和小出血无超额发生,食管胃静脉曲张破裂出血发生率更低。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、ISI Web of Science、SCOPUS和Cochrane数据库截至2017年2月14日,纳入8项研究共353例肝硬化合并门静脉血栓患者,比较抗凝治疗(低分子肝素或华法林)与无治疗。
主要发现
- 抗凝组门静脉血栓再通比例为71%,无抗凝组为42%(P<.0001)。
- 6项研究共217例患者中,抗凝组完全再通比例为53%,无抗凝组为33%(P=.002)。
- 6项研究共225例患者中,抗凝组血栓进展比例为9%,无抗凝组为33%(P<.0001)。
- 6项研究共257例患者中,抗凝组与无抗凝组大出血或小出血比例均为11%,两组无差异。
- 4项研究共158例患者中,抗凝组自发性食管胃静脉曲张破裂出血比例显著低于无抗凝组(P=.04)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver cirrhosis is complicated by bleeding from portal hypertension but also by portal vein thrombosis (PVT). PVT occurs in approximately 20% to 50% of patients with cirrhosis, and is a warning sign for poor outcome. It is a challenge to treat patients with cirrhosis using anticoagulants, because of the perception that the coexistent coagulopathy could promote bleeding. We performed a systematic review and meta-analysis to determine the effects of anticoagulant therapy in patients with cirrhosis and PVT. METHODS: We searched the PubMed, ISI Web of Science, SCOPUS, and Cochrane databases through February 14, 2017, for studies that assessed the effect of anticoagulant therapy vs no treatment in patients with cirrhosis and PVT. We performed a meta-analysis to estimate the effect of anticoagulant treatment vs no therapy on recanalization and progression of PVT in patients with cirrhosis. We also assessed variceal and nonvariceal bleeding. RESULTS: We analyzed data from 8 studies, comprising 353 patients, that assessed the effects of anticoagulant therapy (low-weight heparin or warfarin vs no therapy) in patients with cirrhosis and PVT; these studies reported rates of complete and partial recanalization. A significantly higher proportion of patients treated with anticoagulants underwent PVT recanalization than patients who did not receive anticoagulants (71% vs 42%, respectively; P < .0001). From 6 studies (comprising 217 patients), 53% of patients treated with anticoagulants vs 33% of patients who did not receive anticoagulants had complete PVT recanalization (P = .002). From 6 studies (comprising 225 patients), PVT progressed in 9% of patients treated with anticoagulants vs 33% of patients who did not receive these drugs (P < .0001). Six studies (257 patients) reported rates of any bleeding; there was no difference in the proportions of patients with major or minor bleeding between groups that did vs did not receive anticoagulants (11% for both groups). Four studies (comprising 158 patients) reported rates of spontaneous variceal bleeding, which occurred in a significantly lower proportion of patients who received anticoagulants vs those who did not (P = .04). CONCLUSIONS: Based on a systematic review and meta-analysis, patients with cirrhosis and PVT who receive anticoagulant therapy have increased recanalization and reduced progression of thrombosis, compared with patients who do not receive anticoagulants, with no excess of major and minor bleedings and less incidence of variceal bleeding.
引用
- Loffredo L, Pastori D, Farcomeni A, et al. Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis. Gastroenterology. 2017. PMID: 28479379. doi:10.1053/j.gastro.2017.04.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。